PNH (Paroxysmal Nocturnal Hemoglobinuria) RBC Screening - CD55 & CD 59

No, fasting is not required for this test.

There are no specific preparations needed for this test. However, it's recommended for patients to inform their healthcare provider about any medications or supplements they are taking as some of these might interfere with the test results.

This test should be conducted when a patient exhibits symptoms suggestive of PNH, including but not limited to, dark-colored urine, particularly upon waking, fatigue, shortness of breath, rapid heart rate, and easy bruising or bleeding.

The test detects the absence or deficiency of CD55 and CD59 proteins on red blood cells, which are characteristic features of PNH.

This test is generally conducted when PNH is suspected based on clinical symptoms and other lab findings. The frequency of follow-up testing depends on the patient's condition and the treating physician's judgment.

In a healthy individual, the CD55 and CD59 proteins should be present on the surface of red blood cells. Their absence or deficiency may suggest PNH.

The test involves a routine blood draw, which is a relatively safe procedure. However, some people might experience minor bruising or discomfort at the site of the needle insertion.

The primary factor affecting these protein levels is the presence of the PNH-causing mutation in blood cell-producing stem cells. Certain medications may also impact the immune system and influence the results of this test.

In the event of abnormal results, the patient should consult a hematologist, a medical doctor specializing in blood disorders.

Certain medications, particularly those impacting the immune system, could potentially affect the test results.

Treatment for PNH aims to ease symptoms and prevent complications, including reducing hemolysis, preventing blood clots, and managing symptoms of bone marrow dysfunction. Therapies may include blood transfusions, medications, and in severe cases, stem cell transplantation.

This test, PNH RBC Screening - CD55 & CD59, plays a crucial role in diagnosing PNH and monitoring its progression. It's crucial for patients to understand the importance of this test and its implications on the diagnosis, treatment, and prognosis of PNH. As always, early detection and appropriate treatment significantly impact the overall health outcome in patients with PNH. A thorough discussion with your healthcare provider is always recommended to understand the test results and next steps for management better.